Finland vs Palestine, State of: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Finland
87.0%
in 2024
Palestine, State of
87.0%
in 2024
Finland rank
78th
Palestine, State of rank
78th
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Finland
- Palestine, State of
How they compare
Finland currently reports 87.0% against 87.0% in Palestine, State of, a difference of 0.0%.
The two have swapped places 1 time across 13 shared years of data; in 2012 it was Finland ahead.
Finland ranks 78th and Palestine, State of ranks 78th of 146 countries.
Across the 2 decades both report, Finland averaged higher in 1 and Palestine, State of in 1.
Head to head by decade
| Decade | Finland | Palestine, State of | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 89.6% | 89.1% | 0.5% | Finland |
| 2020s | 85.8% | 93.2% | 7.4% | Palestine, State of |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Finland or Palestine, State of?
- Finland, at 87.0% against 87.0% in Palestine, State of as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Finland and Palestine, State of?
- 0.0%, with Finland ahead.
- How many years of comparable data are there for Finland and Palestine, State of?
- 13 years are reported by both, from 2012 to 2024.
- How do Finland and Palestine, State of rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Finland ranks 78th and Palestine, State of ranks 78th of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.